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Abstract
Introduction: A functional polymorphism within MDM2, SNP309 T>G, has been linked to early
onset cancer. This study examined clinical associations of breast cancer with SNP309 in a Scottish
Caucasian population and investigated additional MDM2 intron 1 polymorphisms.
Methods: Intron 1 of MDM2 was PCR amplified and directly sequenced from 299 breast cancer
patients and 275 cancer free controls and compared with clinical and pathological parameters.
Results:  SNP309 was observed, for the control and breast cancer cohorts respectively, at
frequencies of: T/T = 44.7% and 39.5%; G/T = 42.2% and 47.2%; G/G = 13.1% and 13.4%, indicating
that SNP309 is not a predisposing factor for breast cancer. The 309G/G genotype was associated
with high grade tumours (OR = 1.64, 95%CI = 1.06–2.53, p = 0.025) and greater nodal involvement
(OR = 2.51, 95%CI = 1.26–4.98, p = 0.009). SNP309 was not associated with an earlier age of
cancer diagnosis. No association was observed between genotype and age of breast cancer
diagnosis when patients were stratified by menopausal status and estrogen receptor status. Three
additional low frequency SNPs were identified: 344T>A, 285G>C and 443G>T, the latter two
novel. SNP285 was in complete linkage disequilibrium with SNP309 (D' = 1.0) with the minor alleles
being in phase with each other. Moreover, the 285C/C, 309G/G double homozygous genotype was
only observed in the breast cancer cohort.
Conclusion: SNP309G/G is associated with poor prognostic breast cancer features in the Scottish
population. Additionally, a novel SNP, SNP285, that is in linkage disequilibrium with SNP309, may
also have a role in breast tumorigenesis.
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Introduction
MDM2, encoded by the human homologue of Murine
Double Minute oncogene, is the principal negative regula-
tor of p53, a transcription factor which plays key roles in
cell division and response to DNA damage [1,2]. p53 is
frequently mutated in cancer resulting in defective func-
tions, including apoptotic and cell cycle arrest programs
[3]. MDM2 controls p53 levels and activity by a number
of different mechanisms, including direct inhibition of
the transcriptional activity of p53 [4]. In addition, MDM2
acts as an E3 ubiquitin ligase targeting p53 for nuclear
export and proteosomal degradation [5]. Furthermore, as
MDM2 is a transcriptional target for p53, through the P2
inducible promoter located in intron 1, a finely balanced
negative feedback loop mechanism exists [6].
Development of cancer is often associated with defects in this
p53-MDM2 regulatory circuit, and in cells with wild type p53
other alterations in the p53 pathway are often observed [3].
MDM2 is overexpressed in a number of different cancers and
in breast cancer, where only 30% of tumours have mutated
p53, some 40% display overexpression of MDM2, although
amplifications are rare [7-10].
A single nucleotide polymorphism (SNP) within intron 1
of MDM2, a T to G substitution (T>G) at position 309
(SNP309) (rs2279744), has been shown to lead to
enhanced binding of the Sp1 transcription factor resulting
in elevated levels of both MDM2 mRNA and protein,
thereby attenuating the p53 response [11]. In Li-Fraumeni
patients, individuals homozygous or heterozygous for
SNP309 (G/G or G/T) were shown to develop cancer at an
earlier age than wild type individuals; in patients with
sporadic soft tissue sarcomas, the 309G/G genotype corre-
lated with an average 12 year earlier age of diagnosis [11].
SNP309 was thus postulated as a potential modulator of
cancer susceptibility [11].
Subsequent studies of the SNP309 polymorphism have
demonstrated variable frequencies of 309G/G depending
on race and ethnicity [12-15]. Similarly, the association
between SNP309 and development of cancer has pro-
duced conflicting data (reviewed in [16]). This study
therefore sought to sequence the MDM2 intron 1 region
around SNP309 in detail and determine SNP frequencies
from a control cohort of Scottish Caucasians (n = 275)
and a cohort of geographically matched Scottish Cauca-
sian women with breast cancer (n = 299). The MDM2 SNP
genotypes were examined to determine if they could be
linked to an increased cancer susceptibility, age of cancer
diagnosis, pathological variables and clinical outcome.
Methods
Patient & control samples
Venous blood samples were obtained from otherwise
unselected consenting patients (299) with a diagnosis of
primary breast cancer attending routine breast cancer clin-
ics at Ninewells Hospital, Dundee between 1999 – 2005.
Age at first cancer, menopausal status at diagnosis, family
history of breast cancer, estrogen receptor (ER), progester-
one receptor (PgR), HER-2 expression, pathological nodal
status, tumour grade and Nottingham Prognostic Index
(NPI) were recorded. Tumour grading was carried out by
a specialist pathologist (CAP) and graded as defined by
the NHS Breast Screening Programme guidelines [17].
NPI was calculated as described [18] and then classified
into Poor (>5.4), Moderate (3.4–5.4) and Good (<3.4)
prognosis. ER and PgR were scored according to the quick-
score method [19] and a score ≥ 4/18 was considered to
be positive. HER-2 was evaluated by immunohistochem-
istry and samples scoring 2+ by IHC were then subjected
to fluorescent in situ hybridisation. Samples scoring IHC
3+ or IHC 2+/FISH +ve were considered to be HER-2 pos-
itive [20]. Controls (275) were not matched to cases, but
were similar in age (Mean age = 53.0 yr, Range = 9.8 – 95
yr), had no prior history of cancer and were all of Cauca-
sian descent residing in the Tayside region. All samples
were collected with informed consent in compliance with
all principles of the Helsinki Accord and approved by the
Tayside Local Research Ethics Committee.
Isolation of Genomic DNA
Genomic DNA was extracted from heparinised venous
blood using the Qiagen BioRobot EZ1 (Qiagen), with
standardised protocols (EZ1 DNA Blood Card) as recom-
mended by the manufacturer (Qiagen). Samples were
quantified by spectrophotomeric reading using the Nano-
Drop® ND-1000 (NanoDrop Technologies) and stored at
-80°C.
PCR amplification and sequence analysis
50 μl PCR reactions were set up using a standard premix
of; 10 × PCR buffer (Promega), 10 nmol each dNTP (Epi-
centre Biotechnologies) and 20 pmol primers (MWG Bio-
tech AG): MDM2_SNP309F:
5'GCGGGAGTTCAGGGTAAAGG3', MDM2_SNP309R:
5'CTCCAAT CGCCACTGAACAC3'. Reactions were hot
started with 1 unit of Taq polymerase (Promega) and run
with conditions of denaturation at 95°C for 2 min, fol-
lowed by cycling at 95°C (30 s), 60°C (15 s), 72°C (30 s),
with final elongation at 72°C (5 min). PCR was per-
formed in an Applied Biosystems 9600 thermocycler with
a heated lid. The resulting 287 bp products were then run
on 3% w/v agarose gels (Genseive LE agarose) and visual-
ised using a UV transilluminator. The PCR products gen-
erated were purified using a modification of the ExoSAP
enzymatic clean-up method. 5 μl of PCR product was
incubated with 1 U of Exonuclease I and 1 U of Shrimp
Alkaline Phosphatase for 20 min at 37°C then inactivated
by incubating at 80°C for 15 min. The purified products
were directly sequenced using the ABI PRISM® BigDye™BMC Cancer 2008, 8:281 http://www.biomedcentral.com/1471-2407/8/281
Page 3 of 10
(page number not for citation purposes)
Terminators V 3.0 sequencing kit and run on an ABI 3130
genetic analyzer (Applied Biosystems).
Cloning and Sequencing
Genomic DNA was PCR amplified as above and then
ligated in the vector pGEM®-T Easy according to the man-
ufacturer's instructions (Promega). E. coli JM109 cells
were transformed, white colonies picked and then sub-
jected to plasmid isolation and restriction analysis. Plas-
mids containing the correct insert were sequenced using
the M13 Reverse Primer.
Statistical analysis
The associations between genotypes and risk of breast
cancer were calculated by determining the odds ratios
(ORs) and 95% confidence intervals (CI) from logistic
regression analyses. Associations between genotype and
age of cancer diagnosis were determined using Fisher's
exact test (2 sided) and 2-sample t-tests. Genotype fre-
quencies and association with other clinical parameters
were calculated from logistic regression analyses by deter-
mining the ORs and 95% CIs. Haplotype analysis was per-
formed using Haploview software [21]. All analyses were
performed using Microsoft Excel 2002 SP3 (Microsoft
Corporation) and Minitab Release 14.13 (Minitab Inc.).
The null hypothesis was rejected at an α level of 5% for all
analyses.
Results
SNP309 frequencies in a control and breast cancer 
population
SNP309 frequencies were examined in a control cohort of
Scottish Caucasian individuals (n = 275), consisting of
both males (n = 93) and females (n = 182) (Table 1).
SNP309 genotype frequencies were found to be consistent
with the Hardy-Weinberg equilibrium and similar to
those reported previously [22]. Minor differences
observed between males and females were not statistically
significant (p = 0.301, Fisher's exact test). SNP309 fre-
quencies within the breast cancer population (n = 299)
were: T/T (39.5%), G/T (47.2%) and G/G (13.4%). This
distribution was similar to that of the female control pop-
ulation and logistic regression analysis revealed that no
genotype was significantly associated with an increased
risk of breast cancer (Table 1).
SNP309 and age of breast cancer diagnosis
To test if 309G/G was associated with an earlier age of can-
cer onset, as originally demonstrated [11], the age at first
diagnosis of breast cancer was recorded and median val-
ues plotted with respect to genotype (Figure 1). No statis-
tically significant differences were observed (mean age of
diagnosis in years; T/T = 58.8, T/G = 59.8, G/G = 59.1)
indicating that, in this population, SNP309 is not associ-
ated with age at diagnosis of breast cancer. 13 out of the
299 breast cancer patients had presented with other prior
malignancies. However, the mean ages of any cancer diag-
nosis for each of the genotypes was not significantly
altered, even when this was taken into consideration (data
not shown).
SNP309 and clinicopathological characteristics
We examined SNP309 genotype with respect to a number
of clinicopathological features using logistic regression
analysis (Table 2). 309G/G was significantly associated
with higher tumour grade (OR = 1.64, 95%CI = 1.06–
2.53, p = 0.025) and 309T/G associated with lower
tumour grade (OR = 0.68, 95%CI = 0.53–0.88, p = 0.003).
309T/G was also associated with ductal carcinoma in situ
(DCIS) but not observed with the 309G/G genotype (OR
= 4.21, 95%CI = 1.67–10.44, p = 0.0012). The 309G/G
genotype was also found to be significantly associated
with node positive cancers (OR = 2.51, 95%CI = 1.26–
4.98, p = 0.009). Corroborating evidence demonstrating
that 309G/G was associated with these poorer prognostic
markers was the association of 309G/G with an increased
Nottingham Prognostic Index (NPI) (OR = 1.30, 95%CI =
1.02–1.65, p = 0.031), consistent with NPI values being a
combinatorial score based on tumour grade, nodal status
and tumour size.
SNP309 in relation to menopausal status and tumour ER 
status
Although no associations of SNP309 were observed
between menopausal status or tumour estrogen receptor
(ER) status the two parameters combined have been
Table 1: Genotype frequencies of MDM2 SNP309 in Scottish Caucasian control and breast cancer populations
309 SNP Total 309T/T 309T/G 309G/G
n n (%) n (%) n (%)
Control samples 275 123 (44.7) 116 (42.2) 36 (13.1)
Males 93 48 (51.6) 34 (36.6) 11 (11.8)
Females 182 78 (42.8) 79 (43.4) 25 (13.7)
Breast cancer samples 299 118 (39.5) 141 (47.2) 40 (13.4)
Breast cancer vs. Female controls
OR (95% CI)
1.0 
(referent)
1.18 
(0.80 – 1.87)
1.06
(0.60 – 1.87)
p value - 0.41 0.85
MDM2 SP309 genotype frequencies in Scottish Caucasian control and breast cancer populations. OR = Odds ratio, CI = Confidence interval.BMC Cancer 2008, 8:281 http://www.biomedcentral.com/1471-2407/8/281
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shown to be associated with 309 genotype [23]. This
hypothesis is based on the fact that estrogen can regulate
MDM2 levels, in part, via a promoter site adjacent to
SNP309 and thus in pre-menopausal women, where there
are higher levels of circulating estrogen, and in tumours
that express high levels of the estrogen receptor, the effects
of SNP309 may be exacerbated [24]. Indeed, in breast can-
cer patients, the 309G/G genotype was found more fre-
quently in pre-menopausal patients expressing high
tumour levels of estrogen receptor implying the impor-
tance of this SNP in breast cancer tumorigenesis [23].
To test if SNP309 was more common in ER positive
patients compared to ER negative patients the menopau-
sal status (as determined by factual statement) and ER sta-
tus were then combined and examined. 50 out of 69 pre-
menopausal patients (72%) and 176 out of 226 post-
menopausal patients (78%) were ER positive (ER score ≥
4). The 309G/G genotype was more frequent in the pre-
menopausal ER positive patients (18.0%) compared with
post-menopausal ER positive patients (10.2%) although
non-significantly (Fisher's Exact test; p = 0.143) (Figure
2A). This effect was further heightened by subdividing the
ER positive patients into a group with very high ER expres-
sion (ER score ≥ 12), more similar to the scoring applied
by Bond et al. (Figure 2B) [23]. A higher relative frequency
of the 309G/G genotype was observed in the pre-meno-
pausal highly ER positive patients (22.5%) compared to
the post-menopausal highly ER positive patients (10.9%),
however, again this failed to achieve statistical signifi-
cance (Fisher's Exact test, p = 0.135). Comparing the gen-
otype distributions of ER positive/ER negative in the pre
and post-menopausal patients, whether separated by ER
score ≥ 4 or ≥ 12, suggests that estrogen may well be inter-
acting with SNP309. No difference in the mean age of
diagnosis between genotypes, in any of these groups, was
observed (Figures 2C &2D).
Additional MDM2 intron 1 polymorphisms
Upon sequencing MDM2 intron 1 three additional SNPs
were detected in the control and breast cancer popula-
tions; 344T>A; 285G>C and 443G>T, the latter two repre-
senting previously unreported polymorphisms (Figure 3).
SNP344 and SNP443 were found at very low frequencies;
344T/A heterozygotes (3.3%) and (2.7%), 443G/T heter-
ozygotes (1.8%) and (0.7%) in the control and breast can-
cer cohorts respectively. Both these genotypes were in
Hardy-Weinberg equilibrium and were found at similar
frequencies within the control and breast cancer cohorts
implying that neither is associated with breast cancer.
SNP285 occurred at a slightly higher frequency; heterozy-
gotes (4.4%) and (6.0%) in the control and breast cancer
cohorts respectively. The homozygous 285C/C variant
was observed only in the breast cancer cohort. In addition,
in the breast cancer cohort, the minor allele frequency
(285C) was higher (0.040) compared to the control
(0.022) cohort (OR = 1.87, 95%CI = 0.93–3.78) and
SNP285 appeared to deviate from Hardy-Weinberg equi-
librium (Χ2 = 14.29, p = 0.0001), however, numbers are
too low to draw any firm conclusions. No genotype dis-
played statistically significant differences in mean age at
breast cancer diagnosis.
Each of the intron 1 SNPs was then examined with respect
to SNP309 (Figure 3). The 344T/A and 443G/T SNPs were
both found in combination with the wild type 309
sequence (309T/T) and the heterozygote 309 sequence
(309T/G) but not observed with the homozygous 309
sequence (309G/G). In contrast, 285G/C was found only
with the heterozygous 309 sequence (309T/G) and the
homozygous 309 SNP (309G/G). Moreover, individuals
with the 285/309 double homozygote genotype (285C/C,
309G/G) were only observed in the breast cancer cohort
(Chi-squared, p = 0.175).
The association between the 285G/C heterozygote, only
observed with 309G/G and 309T/G but not 309T/T (in
the control and breast cancer populations), and the
homozygous 285C/C genotype, only observed with
309G/G (in the breast cancer population), suggests that
the 285C and 309G alleles are in linkage disequilibrium.
This was confirmed by carrying out haplotype analysis
Box and whiskers plot showing the age distribution of breast  cancer diagnosis in the breast cancer population with respect  to genotype Figure 1
Box and whiskers plot showing the age distribution of 
breast cancer diagnosis in the breast cancer popula-
tion with respect to genotype. Median values are repre-
sented by a solid horizontal bar, boxes denote the inter-
quartile range and bars indicate the maximum and minimum 
values. Shown above is the mean value and number of sam-
ples per group. Overall mean = 59.3 years (n = 299).
n=40
59.1
n=141
59.8
n=118
58.8BMC Cancer 2008, 8:281 http://www.biomedcentral.com/1471-2407/8/281
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using Haploview software [21] (D' = 1.0) (r2 = 0.047 and
0.071 for the control and breast cancer cohorts respec-
tively) and indicates that the minor alleles are in phase
with each other. This was further verified experimentally,
by PCR amplification of intron 1 from ten individuals het-
erozygous for both loci (285G/C, 309T/G) cloning the
products and then sequencing a minimum of eight colo-
nies from each. In all cases, the 309G allele co-segregated
with the 285C allele, whereas the 309T allele was always
found on the same chromosome as the 285G allele. This
suggests that 285C and 309T are mutually exclusive events
indicating that the SNPs at positions 285 and 309 impact
on each other potentially through chromosomal confor-
mation or by binding accessory factors.
Discussion
The intron 1 region of MDM2 was examined in a Scottish
population of 299 breast cancer patients and 275 cancer
free controls to establish any associations between MDM2
SNPs and breast cancer. In the breast cancer cohort
MDM2 SNP309 was also analysed with respect to age at
cancer diagnosis and pathological variables. The well
characterised SNP309 and three additional SNPs:
344T>A, 285G>C and 443G>T, were identified in both
the control and cancer populations. SNP 344T>A has been
reported previously [11], but not studied in detail, and the
latter two SNPs, to our knowledge, represent novel poly-
morphisms. SNP443G>T lies within the conserved 5'-
RRRCWWGYYY [0,13]RRRCWWGYYY-3' p53 response
Table 2: Association of MDM2 SNP309 genotype and clinicopathological characteristics.
309 SNP Genotype Parameter category n (%) OR (95% CI) p
All patients (n = 299) T/T 118 (39.5)
T/G 141 (47.2)
G/G 40 (13.4)
Menopausal status 
(n = 299)
Pre
(n = 70)
Post
(n = 229)
T/T 32 (45.7) 86 (37.6) 0.71 (0.42 – 1.23) 0.22
T/G 28 (40.0) 113 (49.3) 1.46 (0.85 – 2.52) 0.17
G/G 10 (14.3) 30 (13.1) 0.91 (0.42 – 1.96) 0.78
ER status
(n = 299)
Positive
(n = 226)
Negative
(n = 71)
T/T 91 (40.3) 28 (39.4) 1.11 (0.643 – 1.94) 0.38
T/G 108 (47.8) 31 (43.7) 1.12 (0.65 – 1.93) 0.67
G/G 27 (11.9) 12 (16.9) 0.65 (0.31 – 1.35) 0.24
Tumour Grade 
(n = 298)
DCIS 
(n = 20)
1
(n = 47)
2
(n = 107)
3
(n = 124)
T/T 5 (25.0) 18 (38.3) 42 (39.2) 53 (42.7) 1.21 (0.93 – 1.56) 0.15
T/G 15 (75.0) 25 (53.2) 53 (49.5) 48 (38.7) 0.68 (0.53 – 0.88) 0.003
G/G 0 4 (8.5) 12 (11.2) 23 (18.5) 1.64 (1.06 – 2.53) 0.025
Nodal status
(n = 298)
Positive
(n = 128)
Negative
(n = 170)
T/T 50 (39.1) 67 (39.4) 0.98 (0.62 – 1.58) 0.95
T/G 53 (41.4) 88 (51.8) 0.66 (0.41 – 1.05) 0.07
G/G 25 (19.5) 15 (8.8) 2.51 (1.26 – 4.98) 0.009
NPI
(n = 297)
DCIS
(n = 20)
Good
(n = 72)
Moderate
(n = 123)
Poor
(n = 82)
T/T 5 (25.0) 30 (41.7) 47 (38.2) 35 (42.7) 1.00 (0.85 – 1.19) 0.95
T/G 15 (75.0) 37 (51.4) 59 (48.0) 30 (36.6) 0.87 (0.73 – 1.03) 0.11
G/G 0 5 (6.9) 17 (13.8) 17 (20.7) 1.30 (1.02 – 1.65) 0.03
HER-2 status
(n = 196)
Positive
(n = 47)
Negative
(n = 149)
T/T 18 (38.3) 57 (38.3) 1.00 (0.51 – 1.97) 1.00
T/G 19 (40.4) 73 (49.0) 0.71 (0.36 – 1.37) 0.30
G/G 10 (21.3) 19 (12.8) 1.85 (0.79 – 4.31) 0.16
PgR Status
(n = 294)
Positive
(n = 181)
Negative
(n = 113)
T/T 68 (37.6) 48 (42.5) 0.82 (0.49 – 1.36) 0.40
T/G 90 (49.7) 49 (43.4) 1.29 (0.78 – 2.13) 0.29
G/G 23 (12.7) 16 (14.1) 0.88 (0.42 – 1.88) 0.72
Association of MDM2 SNP309 genotype and clinicopathological characteristics. Each genotype was compared to all the other samples. OR = Odds 
ratio, CI = Confidence interval.BMC Cancer 2008, 8:281 http://www.biomedcentral.com/1471-2407/8/281
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element [6,25], implying that this SNP may alter the abil-
ity of p53 to bind and regulate the MDM2 intron 1 pro-
moter, thereby influencing cancer susceptibility.
However, a larger cohort would be required to test the
clinical significance of this observation.
Neither the 344T>A, nor the 443G>T SNP were observed
with the 309G/G genotype, probably due to the very low
frequencies of each allele. In contrast, SNP285 G>C,
which also has a low prevalence was always observed with
the SNP 309T>G, either in the heterozygous (309T/G) or
homozygous (309G/G) states, but never observed with
the commonest 309T/T allele. This implies that 309SNP
and 285SNP are in linkage disequilibrium and was con-
firmed by haplotype analysis. SNP 285 and SNP309 thus
may influence each other and together modulate the lev-
els of MDM2 produced. Supporting this potential role of
SNP285 enhancing the effects of 309G/G, we observed
the double homozygous genotype (285C/C, 309G/G)
only in the breast cancer cohort and the heterozygous/
homozygous genotype (285G/C, 309G/G) was more
prevalent in the breast cancer cohort. Moreover, SNP285
appeared to deviate from Hardy-Weinberg equilibrium
only in the breast cancer cohort. However, although
potentially interesting, the numbers in our study are
exceptionally small and therefore to verify if the combina-
tion of 309G/G together with the 285C variant may be
breast cancer associated, a much greater number of
patients would be required.
SNP309 genotype distribution in relation to menopausal status and tumour estrogen receptor status Figure 2
SNP309 genotype distribution in relation to menopausal status and tumour estrogen receptor status. A – ER 
positive defined as ER Score ≥ 4. ER negative defined as ER Score <4. B – Highly ER positive breast tumours defined as ER 
Score ≥ 12. Values expressed as a percentage for each group. The mean age of breast cancer diagnosis in relation to menopau-
sal status and tumour estrogen receptor status. C – ER positive defined as ER Score ≥ 4. ER negative defined as ER Score <4. 
D – Highly ER positive breast tumours defined as ER Score ≥ 12. Error bars ± 95%CI.
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The comparable frequencies of T/T, G/T and G/G SNP309
for the control and breast cancer cohorts suggests that the
SNP309G/G genotype did not significantly influence
breast cancer occurrence within this Scottish population,
consistent with studies of both sporadic and familial
breast cancer [15,16,21,26-34]. Similarly, no increased
cancer risk, associated with the 309G/G genotype, has
been observed for other cancer sites including: colorectal
cancer [35-37], uterine leiomyosarcomas [36], squamous
cell carcinoma of the head and neck [36] and lung cancer
[38]. In contrast, several studies, encompassing a diverse
array of other tumour types but also including colorectal
and lung cancer, have reported an increased risk of cancer
occurrence associated with 309G/G [14,39-43]. While the
frequencies observed in our studies are similar to those
reported in other Caucasian populations, SNP309 geno-
typic frequencies do vary considerably between different
ethnic groups [15,31]. For example, approximately 3% of
African Americans carry the double homozygous 309G/G
locus compared to frequencies of approximately 30% in
the Japanese and Korean populations [12,13,15,31]. This
may, in part, explain the discrepant associations between
the 309G/G genotype and cancer. Additionally, from our
work, other SNPs e.g. SNP285, which may also display
variations in demographic frequencies, may influence the
penetrance of SNP309. Furthermore, the higher frequency
G allele in females confirms that appropriate controls
should be used when interpreting results.
We did not observe an association between 309SNP and
earlier age of cancer diagnosis unlike previous investiga-
tions [11,23,33], although the majority of studies in
breast cancer are consistent with our findings [16,26-
28,31,32,34]. Further studies by Bond et al., 2006, showed
that accelerated age of onset in 309G/G patients was
observed only in females and, in diffuse large B-cell lym-
phomas and soft tissue sarcomas the 309G/G genotype
had a higher incidence in pre-menopausal compared to
post-menopausal patients. In our breast cancer cohort,
there was no difference in SNP309 frequencies in pre- and
post-menopausal patients. In the same study Bond et al.
also examined invasive breast cancer stratified by ER sta-
tus in addition to menopausal status and demonstrated
both an increased frequency of 309G/G and an earlier age
of onset associated with ER positive tumours in pre-men-
opausal women. In the present series, a higher frequency
of the 309G/G genotype was observed in the pre-meno-
pausal ER positive patients (ER ≥ 4) compared to the post-
menopausal ER positive patients which was further
enhanced by selecting a highly ER positive group (ER ≥
12). Nonetheless, within any sub-classification no differ-
ences in the mean age of breast cancer diagnosis and gen-
otype were seen.
These findings, demonstrating a higher proportion of
309G/G patients in the ER highly positive pre-menopau-
sal group, are in agreement with Bond et al., 2006 [23].
However, the proportions of pre- and post-menopausal
highly ER positive tumours in the present study are very
different to those reported previously: the highly ER posi-
tive (ER ≥ 12) pre-menopausal group had a frequency of
13.7% and the post-menopausal group had a frequency of
Genotype frequencies of additional MDM2 intron 1 SNPs observed in the control (male & female) and breast cancer popula- tions and their distribution with respect to SNP309 genotype Figure 3
Genotype frequencies of additional MDM2 intron 1 SNPs observed in the control (male & female) and breast 
cancer populations and their distribution with respect to SNP309 genotype. Also shown is the mean age of breast 
cancer diagnosis for each group. Overall mean = 59.3 years (n = 299).
Genotype frequencies of MDM2 additional intron 1 SNPs in the control and breast cancer populations 
     Controls Breast Cancer
 309  SNP 309T/T 309T/G 309G/G
Mean age 
of cancer 
diagnosis
309T/T 309T/G 309G/G 
Total (%)  n  (%) n  (%) n  (%) Total (%) (years)  n (%)  n (%)  n (%) 
285 SNP  G/G  263 (95.6)  123  (44.7) 106 (38.5) 34 (12.4) 278 (93.0) 59.1  118 (39.5) 129 (43.1) 31 (10.4) 
 G/C  12 (4.4)  - -  10 (3.6)  2 (0.7)  18 (6.0)  61.7  - -  12 (4.0)  6 (2.0) 
 C/C  - -  - - - - - -  3  (1.0) 68.7 - - - -  3 (1.0) 
275       299         
344 SNP  T/T  266 (96.7)  117 (42.5) 113 (41.1) 36 (13.1) 291 (97.3) 59.4  114 (38.1) 137 (45.8) 40 (13.4) 
 T/A  9 (3.3)  6 (2.2)  3 (1.1)  - -  8 (2.7)  55.1  4 (1.3)  4 (1.3)  - - 
 A/A  - -  - - - - - -  -  -  -  - - - - - - 
275       299         
443 SNP  G/G  270 (98.2)  122 (44.4) 112 (40.7) 36 (13.1) 297 (99.3) 59.3  117 (39.1) 140 (46.8) 40 (13.4) 
G/T 5 (1.8)  1 (0.4)  4 (1.5)  - -  2 (0.7) 59.0  1 (0.3)  1 (0.3)  - - 
T/T --   --  --  --   - - -  - -  - -  - - 
275       299         BMC Cancer 2008, 8:281 http://www.biomedcentral.com/1471-2407/8/281
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86.3%. In the two breast cancer cohorts studied by Bond
et al., the Caucasian Ashkenazi-Jewish group had values of
35.4% and 64.6% for the pre- and post-menopausal
highly ER positive groups respectively, and values of
50.4% (Pre) and 49.6% (Post) in the second Caucasian
population. This suggests that the demographics of the
Scottish Caucasian population are very different to the
American Caucasian population, which also appear to dif-
fer based on ethnicity. This may also explain, in part, why
we did not observe an association with the mean age of
cancer diagnosis. It also suggests that estrogen may not be
the only variable that impacts on the penetrance of
SNP309.
Compared with clinical and pathological features, the
309G/G genotype appeared to be associated with higher
tumour grade and node positive cancers. Combining
these parameters together with tumour size, to calculate
NPI values, it was therefore not unexpected that 309G/G
was linked with an elevated NPI score. From this prelimi-
nary study, the 309G/G genotype in the Scottish breast
cancer population therefore appears to correlate with
poor prognostic indicators, although a much larger cohort
would be required to verify these findings. This associa-
tion of 309G/G with higher grade tumours and increased
nodal involvement is supported by a recent study in
nasopharyngeal carcinoma where the 309G/G genotype
was associated with advanced lymph node metastasis
[39]. Other corroborating evidence comes from the obser-
vation that over-expression of MDM2 in cancer has been
linked with increased levels of metastasis, poorer response
to therapy and bad prognosis [44]. In vitro studies, utilis-
ing cell lines, have also shown that cells gain enhanced
metastatic potential when MDM2 is up-regulated during
hypoxic conditions [45].
Our data, taken together with that of the literature, sug-
gests that the 309 genotype may be influencing the grade
and metastatic potential of breast tumours. However, the
presence of the G allele does not appear to be adding to
this alone as the 309G/T genotype was found to be asso-
ciated with low grade tumours. One potential explanation
for this is that each of the different alleles could be bind-
ing different transcription factors. Indeed, the P2 pro-
moter of MDM2 is known to be regulated by a myriad of
different transcription factors including Sp1, p53, Ap1-
ETS and MYCN [6,46-48]. Levels of these regulatory pro-
teins and whether they are mutant or wild type, modified
or unmodified, could also impact on MDM2 transcription
levels. One key regulator influencing the penetrance of
SNP309 may be p53, particularly as it is known to be hap-
loinsufficient [49]. p53 has been examined in terms of the
p53 polymorphism Arg72Pro [13,29,32,37,50] and muta-
tional status of p53 [26,41,51-54] with conflicting results.
Similarly, SNP285G>C that is in linkage disequilibrium
with SNP309, identified in this study, may play a modu-
latory role influencing SNP309 penetrance. Thus,
although all breast cancers can be classified on a histolog-
ical and pathological level, this may in fact be determined
by underlying SNP differences, some of which have
greater influence than others depending on the popula-
tion and the additional parameters examined.
Conclusion
In conclusion, within this Scottish population the MDM2
309 polymorphism was found to associate with high
grade cancers with greater nodal involvement and by
implication poorer prognosis, but had no impact on the
age of diagnosis of breast cancer. Furthermore, SNP309 is
in linkage disequilibrium with SNP285 which may further
modulate the penetrance of polymorphism effects.
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